CSL Limited (CSLLY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Melbourne, VIC, Australia. The current CEO is Gordon Naylor DipCompSc.
CSLLY has IPO date of 2009-12-29, 32,698 full-time employees, listed on the Other OTC, a market capitalization of $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.
